[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-435657-105":59,"doc-detail-435657-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","perilesional-topical-sirna-for-keloid-regression-delivered-via-microneedle-patch-a-novel-frontier-in-scar-modulation","Perilesional topical siRNA for keloid regression delivered via microneedle patch: a novel frontier in scar modulation","","Keloids are benign, disfiguring fibrous proliferations driven by abnormal wound healing, excessive collagen deposition, persistent inflammation, and aberrant fibroblast signaling. The letter argues that existing therapies such as cryotherapy, steroids, and lasers often fail and face high recurrence, motivating targeted molecular interventions. Recent advances in molecular dermatology suggest siRNA can silence key genes involved in fibrosis, but delivery remains the main barrier due to instability and limited tissue penetration. Microneedle patches may enable minimally invasive, precise transdermal delivery to the dermis, achieving effective gene silencing in preclinical work and early trials, while highlighting remaining limitations in dosing, penetration barriers, off-target effects, immune reactivity, and long-term safety.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/perilesional-topical-sirna-for-keloid-regression-delivered-via-microneedle-patch-a-novel-frontier-in-scar-modulation/435657/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/perilesional-topical-sirna-for-keloid-regression-delivered-via-microneedle-patch-a-novel-frontier-in-scar-modulation/435657.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are current keloid treatments often insufficient?","Question",{"text":113,"@type":114},"They frequently fail to produce appreciable results and have consistently high recurrence rates, leading to ongoing disfigurement and aesthetic lesions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does siRNA therapy aim to address keloids?",{"text":118,"@type":114},"siRNAs can selectively silence fibrosis-related genes such as TGF-β, CTGF, and COL1A1, thereby reducing fibroblast proliferation and collagen/matrix deposition.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is microneedle patch delivery highlighted as important for siRNA?",{"text":122,"@type":114},"Because siRNAs are unstable and face poor tissue penetration, microneedle patches offer minimally invasive, biodegradable, and less toxic transdermal delivery that targets the dermis with the required dose.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},435657,1790796846,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":24,"preview_page_count":4},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Letter to the Editor  \nPerilesional topical siRNA for keloid regression delivered via microneedle patch: a novel frontier in scar modulation  \nFahad Amin, MBBSa , Muhammad Talha, MBBSa , Raghabendra Kumar Mahato, MBBSb ,*  \nTo the Editor,  \nKeloids are benign proliferations of fibrous tissue that are formed as a result of abnormal wound healing. They are characterized by excessive collagen deposition, persistent inflammation, and aberrant fibroblast signaling cascades. Their margins extend way beyond that of the wound and result in disfigurement and esthetic lesions. Managing keloids remains a persistent issue in surgical procedures and wound management. Traditional treatments like cryotherapy, steroid injections, and laser therapy often fail to yield appreciable results [1] . Moreover, the high rate of recurrence of keloids consistently downplays any current therapies used to control them. This highlights the need for a novel therapeutic modality that specifically targets the molecular mechanisms ofkeloids to get rid of them permanently.  \nRecent advances in molecular dermatology have demonstrated siRNAs as a promising tool to treat keloids. These drugs can selectively silence the genes such as TGF-BETA, CTGF, and COL1A1 . They can thus reduce the fibroblast proliferation and collagen and matrix deposition [2] . The major challenge faced by siRNA therapy is the delivery of such drugs to the target tissue. High rates of degradation and low tissue penetration make them a poor choice in dermal procedures. In this regard, microneedle patch technology has recently emerged as a minimally invasive method to deliver drugs transdermally. These patches are composed of biodegradable materials and are rarely toxic. This technique can painlessly deliver the required therapeutic dose directly to the dermis without causing extensive tissue damage [3] .  \naDepartment of Medicine, King Edward Medical University, Lahore, Pakistan and bDepartment of Medicine, Gandaki Medical College, Teaching Hospital and Research Center, Pokhara, Nepal  \nSponsorships or competing interests that may be relevant to content are disclosed at the end of this article.  \n*Corresponding author. Address: Department of Medicine, Gandaki Medical College, Teaching Hospital and Research Center, Pokhara 33700, Nepal. Tel.: +977-9745829807. E-mail: [102raghabendrakumarmahato@gmail.com](102raghabendrakumarmahato@gmail.com)[ ](102raghabendrakumarmahato@gmail.com)(R. K. Mahato).  \nCopyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nAnnals of Medicine & Surgery (2026) 88:1084–1085  \nReceived 13 November 2025; Accepted 17 November 2025  \nPublished online 25 November 2025  \n[http://dx.doi.org/10.1097/MS9.0000000000004435](http://dx.doi.org/10.1097/MS9.0000000000004435)  \nIntegrating siRNA delivery with microneedle patch delivery seems to be the ideal treatment for keloids. Preclinical studies have shown that microneedle-mediated siRNA delivery achieves effective gene silencing with ideal penetration and minimal systemic adverse effects. A recent randomized controlled trial evaluated the efficacy of microneedle-mediated siRNA delivery in post-operative scar formation [4] . Results showed a statistically significant benefit of siRNA therapy in reducing the scar occurrence as well as scar volume. The treatment group was also associated with regression of any existing scars as well. These promising results suggest that such a combination may also be used in treating keloids.  \nDespite these successes, several limitations hinder the widespread adoption and application of this technique. First, siRNAsare very unstable molecules and prone","cbCaiq0TA4tH0PMa","https://ap.wps.com/l/cbCaiq0TA4tH0PMa","pdf",176472,"English","# Letter to the Editor\n## Background on keloids and limitations of current therapies\n## Rationale for siRNA and the microneedle patch delivery approach\n## Evidence from preclinical studies and trials\n## Limitations and need for further research\n## Conclusion and future directions\n## Transparency in AI use (TITAN guideline)","[{\"question\":\"Why are current keloid treatments often insufficient?\",\"answer\":\"They frequently fail to produce appreciable results and have consistently high recurrence rates, leading to ongoing disfigurement and aesthetic lesions.\"},{\"question\":\"How does siRNA therapy aim to address keloids?\",\"answer\":\"siRNAs can selectively silence fibrosis-related genes such as TGF-β, CTGF, and COL1A1, thereby reducing fibroblast proliferation and collagen/matrix deposition.\"},{\"question\":\"Why is microneedle patch delivery highlighted as important for siRNA?\",\"answer\":\"Because siRNAs are unstable and face poor tissue penetration, microneedle patches offer minimally invasive, biodegradable, and less toxic transdermal delivery that targets the dermis with the required dose.\"}]","Perilesional topical siRNA for keloid regression delivered via microneedle patch: a novel frontier in scar modulation | PDF",1790674643]